SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

LIVMARLI

MIRM·Mirum Pharmaceuticals, Inc.
BULLISH
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized (first FDA approval September 2021 for Alagille syndrome; PFIC label expansion July 2024; tablet formulation April 2025). A third label expansion for ultra-rare cholestatic liver diseases is expected to be filed with regulators in H1 2027.
Why 4/10
LIVMARLI is already approved and commercialized for Alagille Syndrome (2021) and PFIC (2024), with no pending PDUFA date. The next hard catalyst is a regulatory submission for label expansion into ultra-rare cholestatic liver diseases following the positive Phase 3 EXPAND readout, which Mirum guided would be part of five potential H1 2027 submissions. Since the drug is approved with no pending binary regulatory decision, the impactScore is capped at 5 per the rubric.
Actionable Insight BULLISH

The next catalyst for LIVMARLI is a regulatory submission for label expansion into ultra-rare cholestatic liver diseases (including biliary atresia) following the positive Phase 3 EXPAND readout. Mirum guided for five potential regulatory submissions across its portfolio in H1 2027; a filing acceptance would be a positive signal. Watch for FDA submission announcements in early 2027.

Price Chart

Loading chart...

Executive Summary

LIVMARLI (maralixibat) is an oral IBAT inhibitor approved for cholestatic pruritus in Alagille syndrome (2021) and PFIC (2024), and is the primary revenue driver for Mirum Pharmaceuticals (MIRM). The drug generated strong Q3 2026 sales that helped lift full-year guidance to $715-720M. In October 2026, the Phase 3 EXPAND study met its primary endpoint with highly significant results, positioning LIVMARLI for a potential third label expansion into ultra-rare cholestatic liver diseases including biliary atresia. Mirum expects to file regulatory submissions in H1 2027. Analyst consensus is strongly bullish with a mean price target of $154 (65% upside), though insider selling and some institutional trimming in Q3 temper the outlook. The stock trades at $93.99 as of November 13, 2026.

How It Works

LIVMARLI (maralixibat) is an oral liquid or tablet that blocks a protein called the ileal bile acid transporter (IBAT) in the gut. In rare liver diseases like Alagille syndrome and PFIC, bile acids build up to toxic levels because the liver cannot properly drain them. By blocking bile acid reabsorption in the intestine, LIVMARLI causes excess bile acids to be excreted in the stool instead of recirculating back to the liver, which reduces the severe itching (pruritus) and liver damage these patients experience.

Trial Status

LIVMARLI is approved in the US for cholestatic pruritus in Alagille syndrome (2021) and PFIC (2024), with a tablet formulation approved in 2025. It is also approved in the EU for PFIC and in Canada for ALGS and PFIC. The Phase 3 EXPAND study in ultra-rare cholestatic liver diseases (including biliary atresia) met its primary endpoint in October 2026 with statistically significant pruritus reduction (p=0.0004) and a 69% reduction in serum bile acids (p<0.0001). Mirum is preparing regulatory submissions for H1 2027.

The Two-Sided Case

▲ Bull Case5
LIVMARLI is already a proven commercial product with strong sales momentum: Mirum reported Q3 2026 net product sales of $185.7M and raised full-year 2026 guidance to $715-720M, driven largely by LIVMARLI demand.
The Phase 3 EXPAND study succeeded with highly statistically significant results (p=0.0004 for pruritus reduction, p<0.0001 for serum bile acid reduction), positioning LIVMARLI for a third rare liver indication covering biliary atresia and other ultra-rare cholestatic diseases.
Analyst consensus is overwhelmingly bullish: 20 of 21 analysts rate MIRM as Buy/Strong Buy/Buy (12 Buy, 8 Strong Buy, 1 Hold), with a mean price target of $154 (65% upside from the $93.33 close) and a high target of $194.
Major institutional investors added positions in Q3 2026: UBS added 90% ($61.7M position), Jane Street initiated a new $24.4M position, and JPMorgan added 66% ($12.1M).
Mirum is targeting cash flow positive in 2027, and the company has multiple pipeline catalysts beyond LIVMARLI including volixibat (Phase 2b in PBC, Breakthrough Therapy designation) and brelovitug (Phase 3 in HDV).
▼ Bear Case5
LIVMARLI already faces competition from other IBAT inhibitors and bile acid modulators in rare cholestatic liver diseases, which could pressure market share and pricing.
Insider selling has been notable: CEO Christopher Peetz sold $1.8M in stock on Nov 4, 2026 (via 10b5-1 plan), and director Laura Brege sold ~$1.33M on Nov 11, 2026 (not under a 10b5-1 plan).
Several large institutional holders trimmed positions in Q3 2026, including Federated Hermes (-63%), Nuveen (-60%), and Principal Financial (-52%), suggesting some profit-taking at elevated valuations.
The company still reported a net loss of $40.8M in Q3 2026, though this is partly due to investment in pipeline expansion.
The EXPAND label expansion will require FDA submission and review, with no guarantee of approval or timeline.

Upcoming Catalysts

  • Regulatory submission for LIVMARLI label expansion into ultra-rare cholestatic liver diseases (biliary atresia) expected H1 2027
  • Potential FDA acceptance of supplemental NDA filing for EXPAND indication
  • Continued commercial sales growth and potential cash flow positive milestone in 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Mirum Pharmaceuticals, Inc. CLUSTER MIRM ·Originating report

Sources · 9

Hover a chip for the title
1 fiercepharma.com2 morningstar.com3 businesswire.com4 nasdaq.com5 businesswire.com6 seekingalpha.com7 bioworld.com8 streetinsider.com9 biospace.com